Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!
Details in Brand-New Special Report!

CLBS Insider Trading (Caladrius Biosciences)

Insider Ownership Percentage: 10.30%
Insider Buying (Last 12 Months): $99,945.00
Insider Selling (Last 12 Months): $0.00

Caladrius Biosciences Insider Trading History Chart

Caladrius Biosciences Share Price & Price History

$1.55
▼ -0.01 (-0.64%)
As of 06/21/2021 03:43 PM ET
Days: 30 | 90 | 365
Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!
Details in Brand-New Special Report!

Caladrius Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/9/2020Michael H. DavidsonDirectorBuy55,525$1.80$99,945.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Caladrius Biosciences (NASDAQ:CLBS)

11.29% of Caladrius Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Caladrius Biosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/18/2021Millennium Management LLC44,405$86K0.0%N/A0.075%Search for SEC Filing on Google Icon
5/18/2021Morgan Stanley70,537$0.14M0.0%+533.0%0.119%Search for SEC Filing on Google Icon
5/14/2021Dimensional Fund Advisors LP61,506$0.12M0.0%+199.3%0.103%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC1,460,155$2.82M0.0%+39.6%2.454%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp85,855$0.17M0.0%+398.3%0.144%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC318,153$0.61M0.0%+583.6%0.535%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.1,037,975$2M0.0%+3,340.8%1.745%Search for SEC Filing on Google Icon
4/28/2021Game Plan Financial Advisors LLC15,000$29K0.0%N/A0.025%Search for SEC Filing on Google Icon
3/8/2021Dimensional Fund Advisors LP20,548$29K0.0%-37.1%0.062%Search for SEC Filing on Google Icon
2/25/2021Dimensional Fund Advisors LP20,548$29K0.0%-37.1%0.062%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC52,599$75K0.0%N/A0.160%Search for SEC Filing on Google Icon
2/16/2021Squarepoint Ops LLC20,637$30K0.0%N/A0.063%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC1,045,855$1.50M0.0%+12.8%3.173%Search for SEC Filing on Google Icon
11/9/2020Acadian Asset Management LLC156,668$0.28M0.0%+119.0%0.811%Search for SEC Filing on Google Icon
5/15/2020Summit Trail Advisors LLC17,730$32K0.0%N/A0.138%Search for SEC Filing on Google Icon
2/13/2020Renaissance Technologies LLC411,401$1.03M0.0%+5.0%3.956%Search for SEC Filing on Google Icon
8/14/2019Vanguard Group Inc.207,973$0.47M0.0%+7.6%1.999%Search for SEC Filing on Google Icon
8/13/2019BlackRock Inc.29,107$66K0.0%-42.6%0.280%Search for SEC Filing on Google Icon
8/12/2019Renaissance Technologies LLC380,336$0.87M0.0%+20.6%3.663%Search for SEC Filing on Google Icon
5/9/2019Wesbanco Bank Inc.10,000$36K0.0%N/A0.096%Search for SEC Filing on Google Icon
4/1/2019Deutsche Bank AG51,011$0.18M0.0%-11.0%0.513%Search for SEC Filing on Google Icon
12/13/2018Vanguard Group Inc202,568$1.20M0.0%+2.9%2.059%Search for SEC Filing on Google Icon
11/13/2018Renaissance Technologies LLC280,864$1.66M0.0%+42.9%2.854%Search for SEC Filing on Google Icon
8/13/2018Renaissance Technologies LLC196,563$1.27M0.0%+33.7%2.022%Search for SEC Filing on Google Icon
5/11/2018Dimensional Fund Advisors LP33,765$0.20M0.0%N/A0.353%Search for SEC Filing on Google Icon
5/10/2018JPMorgan Chase & Co.18,771$0.11M0.0%N/A0.196%Search for SEC Filing on Google Icon
2/15/2018Macquarie Group Ltd.29,890$0.11M0.0%+321.0%0.316%Search for SEC Filing on Google Icon
5/12/2017KCG Holdings Inc.36,291$0.18M0.0%+74.6%0.000%Search for SEC Filing on Google Icon
5/12/2017Renaissance Technologies LLC97,552$0.49M0.0%+34.3%0.000%Search for SEC Filing on Google Icon
2/13/2017Renaissance Technologies LLC72,652$0.21M0.0%+149.2%0.000%Search for SEC Filing on Google Icon
11/15/2016Knoll Capital Management LP55,781$0.27M0.5%N/A0.000%Search for SEC Filing on Google Icon
5/16/2016Jacobs Levy Equity Management Inc.165,691$0.12M0.0%N/A0.281%Search for SEC Filing on Google Icon
5/13/2016Geode Capital Management LLC293,305$0.22M0.0%0.0%0.530%Search for SEC Filing on Google Icon
5/10/2016BlackRock Institutional Trust Company N.A.246,414$0.19M0.0%No Change0.445%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Caladrius Biosciences logo
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Read More on Caladrius Biosciences

Today's Range

Now: $1.55
$1.54
$1.61

50 Day Range

MA: $1.55
$1.40
$1.68

52 Week Range

Now: $1.55
$1.25
$4.89

Volume

10,697 shs

Average Volume

3,793,428 shs

Market Capitalization

$92.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Who are the company insiders with the largest holdings of Caladrius Biosciences?

Caladrius Biosciences' top insider investors include:
  1. Michael H Davidson (Director)

Who are the major institutional investors of Caladrius Biosciences?

Caladrius Biosciences' top institutional shareholders include:
  1. Renaissance Technologies LLC — 2.45%
  2. BlackRock Inc. — 1.74%
  3. Geode Capital Management LLC — 0.53%
  4. Northern Trust Corp — 0.14%
  5. Morgan Stanley — 0.12%
  6. Dimensional Fund Advisors LP — 0.10%

Which major investors are buying Caladrius Biosciences stock?

During the last quarter, CLBS stock was acquired by institutional investors including:
  1. BlackRock Inc.
  2. Renaissance Technologies LLC
  3. Geode Capital Management LLC
  4. Northern Trust Corp
  5. Morgan Stanley
  6. Millennium Management LLC
  7. Dimensional Fund Advisors LP
  8. Game Plan Financial Advisors LLC
Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!
Details in Brand-New Special Report!